Volume 18, Number 10—October 2012
Research
Autochthonous and Dormant Cryptococcus gattii Infections in Europe
Table
Source of isolation |
Genotype
|
Total† | Total (%) | |||||
---|---|---|---|---|---|---|---|---|
AFLP4/VGI | AFLP5/VGIII | AFLP6/VGII | AFLP7/VGIV | AFLP10/VGIV | ||||
All C. gattii isolates | 146 | 22 | 108 | 13 | 2 | 0 | 291 (100) | |
Human |
84 | 16 | 68 | 12 | 2 | 0 | 182 (62.5)‡ | |
Environment |
37 | 5 | 17 | 0 | 0 | 0 | 59 (20.3)‡ | |
Animal |
24 | 0 | 23 | 1 | 0 | 0 | 48 (16.5)‡ | |
Unknown |
1 | 1 | 0 | 0 | 0 | 0 | 2 (0.7)‡ | |
Africa | ||||||||
Human |
18 | 0 | 3 | 8 | 0 | 29 | 36 (12.7)§ | |
Environment |
6 | 0 | 0 | 0 | 0 | 6 | ||
Animal |
0 | 0 | 0 | 1 | 0 | 1 | ||
Asia (clinical) | 19 | 0 | 5 | 2 | 0 | 26 | 26 (8.9)§ | |
Australia | ||||||||
Human |
2 | 1 | 8 | 0 | 0 | 11 | 18 (6.2)§ | |
Environment |
5 | 0 | 1 | 0 | 0 | 6 | ||
Animal |
0 | 0 | 1 | 0 | 0 | 1 | ||
Europe¶ | ||||||||
Human |
29# | 1** | 23†† | 2‡‡ | 2§§ | 57 | 100 (34.4)§ | |
Environment |
22 | 0 | 0 | 0 | 0 | 22 | ||
Animal |
21 | 0 | 0 | 0 | 0 | 21 | ||
North America¶ | ||||||||
Human |
3 | 8 | 19 | 0 | 0 | 30 | 69 (23.7)§ | |
Environment |
4 | 3 | 10 | 0 | 0 | 17 | ||
Animal |
2 | 0 | 20 | 0 | 0 | 22 | ||
South America¶ | ||||||||
Human |
12 | 3 | 10 | 0 | 0 | 25 | 36 (12.4)§ | |
Environment |
0 | 2 | 6 | 0 | 0 | 8 | ||
Animal |
1 | 0 | 2 | 0 | 0 | 3 | ||
Unknown |
||||||||
Human |
1 | 3 | 0 | 0 | 0 | 4 | 6 (2.1)§ | |
Unknown |
1 | 1 | 0 | 0 | 0 | 2 |
*The number of C. gattii isolates is provided for each geographic area and further subdivided per genotype and source of isolation. AFLP, amplified fragment length polymorphism; human, human clinical patient.
†Total number of isolates per geographic area.
‡The percentage of isolates is given for the source of isolation subset.
§The percentage of isolates is given as a percentage of all isolates.
¶Ten interspecies hybrid C. gattii × C. neoformans isolates were excluded from the set of isolates from Europe (n = 7), North America (n = 1), and South America (n = 2).
#Twelve patients with an autochthonous acquired infection (16 isolates) and 11 patients with an infection acquired outside Europe (13 isolates).
**Infection acquired outside Europe.
††Four patients with an autochthonous infection (10 isolates) and 10 patients with an infection acquired outside Europe (13 isolates).
‡‡Two phenotypically different isolates from an emigrant from Zambia.
§§Two phenotypically different isolates from an emigrant from Mexico.